COLL 33.14 (+2.19%)
US19459J1043Drug ManufacturersDrug Manufacturers - Specialty & Generic

Collegium Pharmaceutical (COLL) Stock Highlights

33.14 | +2.19%
2024-06-03 02:04:56
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. It is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release & immediate-release formulations of tapentadol.

Statistics

Range Today
32.26 33.5
Volume Today 566.5K
Range 1 Year
20.83 40.95
Volume 1 Year 94.86M
Range 3 Year
14.04 40.95
Volume 3 Year 257.62M
Range 10 Year
7.37 40.95
Volume 10 Year 854.33M

Highlights

Market Capitalization 1.08B (small)
Floating Shares 30.44M
Current Price 33.14
Price To Earnings 13
Price To Revenue 2.46
Price To Book 4.88
Earnings Per Share 2.51
Payout Ratio 0%

Performance

Latest +2.19%
1 Month -10.72%
3 Months -11.67%
6 Months +29.3%
1 Year +52.51%
3 Years +38.49%
5 Years +188.42%
10 Years +176.17%

Benchmarks


Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.